Recruiting Essential Tremor Studies in Bakersfield
A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
EYE-RES-103 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic ma...
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
This study will evaluate the efficacy, safety, and Pharmacokinetics (PK) of the PDS with ranibizumab in participants with DME when treated every 24 weeks (Q24W) compared with intravitreal (IVT) ranibi...
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripheral Neuropathy (DPN)...
Comparing Radiation Therapy to Usual Care for Patients With High-Risk Bone Asymptomatic Metastases, PREEMPT Trial
This phase III trial compares the effect of adding radiation therapy to usual care on the occurrence of bone-related complications in cancer patients with high-risk bone metastases that are not causin...
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join the study. The purpose of this study is to find ou...
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (AAVIATE)
RGX-314 is being developed as a potential novel one-time gene therapy treatment for the treatment of neovascular (wet) age related macular degeneration (wet AMD). Wet AMD is characterized by loss of v...
Safety of a Single, Intravitreal Injection of 8.8M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
This study evaluates the safety of a single injection of jCell (famzeretcel) comprising 8.8 million (8.8M) retinal progenitor cells over a six-month study period in a cohort of adult subjects with RP....
About Essential Tremor Clinical Trials in Bakersfield
Essential tremor is one of the most common movement disorders, causing involuntary shaking, most often in the hands. It is different from Parkinson's disease, though the two can be confused. Treatment includes medications, focused ultrasound, and deep brain stimulation for severe cases.
There are currently 7 essential tremor clinical trials recruiting participants in Bakersfield, CA. These studies are seeking a combined 2,527 participants. Research is being sponsored by EyeBiotech Ltd., Hoffmann-La Roche, Vertex Pharmaceuticals Incorporated and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Essential Tremor Clinical Trials in Bakersfield — FAQ
Are there essential tremor clinical trials in Bakersfield?
Yes, there are 7 essential tremor clinical trials currently recruiting in Bakersfield, CA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Bakersfield?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Bakersfield research site will contact you about next steps.
Are clinical trials in Bakersfield free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Bakersfield studies also compensate for your time and travel.
What essential tremor treatments are being tested?
The 7 active trials in Bakersfield are testing new therapies including novel drugs, biologics, and treatment approaches for essential tremor.
Data updated March 2, 2026 from ClinicalTrials.gov